AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback.

In addition, the FDA denied full approval for andexanet alfa (Andexxa) a month after an advisory committee highlighted uncertainties about which dose and in which patients it could best be used.